ATE213633T1 - Lamotrigin haltiges arzneimittel - Google Patents

Lamotrigin haltiges arzneimittel

Info

Publication number
ATE213633T1
ATE213633T1 AT95939352T AT95939352T ATE213633T1 AT E213633 T1 ATE213633 T1 AT E213633T1 AT 95939352 T AT95939352 T AT 95939352T AT 95939352 T AT95939352 T AT 95939352T AT E213633 T1 ATE213633 T1 AT E213633T1
Authority
AT
Austria
Prior art keywords
pct
date jun
lamotrigine
containing lamotrigine
sec
Prior art date
Application number
AT95939352T
Other languages
English (en)
Inventor
Simon Philip Hiskett
Susan Ann Taylor
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE213633T1 publication Critical patent/ATE213633T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
AT95939352T 1994-12-07 1995-12-07 Lamotrigin haltiges arzneimittel ATE213633T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9424766.5A GB9424766D0 (en) 1994-12-07 1994-12-07 Pharmaceutical composition
PCT/GB1995/002865 WO1996017611A1 (en) 1994-12-07 1995-12-07 Pharmaceutical composition comprising lamotrigine

Publications (1)

Publication Number Publication Date
ATE213633T1 true ATE213633T1 (de) 2002-03-15

Family

ID=10765604

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95939352T ATE213633T1 (de) 1994-12-07 1995-12-07 Lamotrigin haltiges arzneimittel

Country Status (19)

Country Link
US (1) US5861179A (de)
EP (1) EP0797441B1 (de)
JP (1) JP2977284B2 (de)
CN (1) CN1174505A (de)
AT (1) ATE213633T1 (de)
AU (1) AU696406B2 (de)
BR (1) BR9509975A (de)
CA (1) CA2207284A1 (de)
CZ (1) CZ171797A3 (de)
DE (1) DE69525649T2 (de)
ES (1) ES2172600T3 (de)
FI (1) FI972434L (de)
GB (1) GB9424766D0 (de)
HU (1) HUT77367A (de)
NO (1) NO972623L (de)
NZ (1) NZ296573A (de)
PL (1) PL320560A1 (de)
RU (1) RU2160106C2 (de)
WO (1) WO1996017611A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
DE19603984A1 (de) * 1996-02-05 1997-08-07 Bayer Ag Granulate von Triazinen
JPH11506473A (ja) * 1997-02-25 1999-06-08 ザ、プロクター、エンド、ギャンブル、カンパニー 湿式粒状化方法
JP2002521322A (ja) * 1998-07-23 2002-07-16 ノボ ノルディスク アクティーゼルスカブ 安定な医薬製剤の製造のための湿式顆粒化方法
ATE335069T1 (de) * 1999-06-21 2006-08-15 Procter & Gamble Verfahren zur herstellung von reinigungsmittelgranulaten in einem wirbelschichtgranulator mit rückführung von unproportionierten teilchen
IL157608A0 (en) 2001-02-27 2004-03-28 Teva Pharma New crystal forms of lamotrigine and processes for their preparations
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
ES2282628T3 (es) * 2002-04-23 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicon farmaceutica que contiene particulas de lamotrigina de morfologia definida.
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1608342A2 (de) * 2003-03-21 2005-12-28 Ranbaxy Laboratories, Ltd. Stabile arzneizusammensetzungen mit lamotrigine und deren herstellungsverfahren
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
EP3395340B8 (de) 2003-09-12 2019-12-11 Amgen Inc. Schnellauflösungsformulierung enthaltend cinacalcet hcl
MXPA06013870A (es) * 2004-05-31 2007-04-25 Senju Pharma Co Agente para visualizar tejido transparente.
US20100016322A1 (en) * 2007-02-28 2010-01-21 Nagesh Nagaraju Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
MX2012010229A (es) 2010-03-04 2012-12-05 Wockhardt Ltd Forma de dosis de liberacion modificada.
WO2018071547A1 (en) 2016-10-11 2018-04-19 Aucta Pharmaceuticals Powder for oral suspension containing lamotrigine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
DD151309A5 (de) * 1979-06-01 1981-10-14 Wellcome Found Verfahren zur herstellung von substituierten aminotriazinen
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
AU635040B2 (en) * 1989-06-30 1993-03-11 Sumitomo Electric Industries, Ltd. Substrate having a superconductor layer
BE1004461A5 (fr) * 1991-01-30 1992-11-24 Wellcome Found Comprimes dispersables dans l'eau.
GB2278057B (en) * 1991-01-30 1995-02-01 Wellcome Found Water-dispersible tablets containing lamotrigine
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2700114A1 (fr) * 1993-01-07 1994-07-08 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
GB9305692D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9305693D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
FR2702149B1 (fr) * 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement du neuro-sida.
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets

Also Published As

Publication number Publication date
EP0797441B1 (de) 2002-02-27
FI972434A7 (fi) 1997-06-09
CZ171797A3 (en) 1997-11-12
CN1174505A (zh) 1998-02-25
GB9424766D0 (en) 1995-02-08
NO972623D0 (no) 1997-06-06
RU2160106C2 (ru) 2000-12-10
WO1996017611A1 (en) 1996-06-13
EP0797441A1 (de) 1997-10-01
DE69525649D1 (de) 2002-04-04
HUT77367A (hu) 1998-03-30
AU4121196A (en) 1996-06-26
CA2207284A1 (en) 1996-06-13
US5861179A (en) 1999-01-19
AU696406B2 (en) 1998-09-10
NO972623L (no) 1997-08-06
JP2977284B2 (ja) 1999-11-15
JPH10510255A (ja) 1998-10-06
PL320560A1 (en) 1997-10-13
FI972434A0 (fi) 1997-06-06
NZ296573A (en) 1997-08-22
DE69525649T2 (de) 2002-09-05
MX9704103A (es) 1997-09-30
BR9509975A (pt) 1998-06-09
ES2172600T3 (es) 2002-10-01
FI972434L (fi) 1997-06-09

Similar Documents

Publication Publication Date Title
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
NO963053D0 (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
ATE260646T1 (de) Schnell zerfallende orale dosierungsform
SE8804629D0 (sv) New therapeutically active compounds
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
DZ1794A1 (fr) Nouvelle formule pharmaceutique.
BR9508655A (pt) Composição farmacêutica aquosa estéril
AU2614995A (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
ATE259815T1 (de) Neue antagonistische verbindungen
DK0680326T3 (da) Farmaceutisk formulering af nikotinafhængighed.
SE8804628D0 (sv) New compounds
EE03385B1 (et) Angiotensiini II tüüp 1 retseptori antagonistide kasutamine düspeptiliste sümptomite profülaktikas ja/või ravis kasutatava ravimi valmistamiseks ja angiotensiini II tüüp 1 retseptori antagoniste sisaldavad ravimpreparaadid
UA41978C2 (uk) N-метил-n-[(1s)-1-феніл-2-((3s)-3-гідроксипіролідин-1-іл)етил]-2,2- дифенілацетамід гідрохлорид, спосіб його отримання та фармацевтична композиція
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
BR9306870A (pt) Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol
DK0678089T3 (da) N-Acylpyrrolidiner og lægemidler til behandling eller forebyggelse af cholecystokinin- og gastrin-relaterede forstyrrelser
GEP20043377B (en) Pharmaceutical Complex
IL108283A0 (en) Use of riluzole for promoting restoration following radiation
JO1653B1 (en) The current benzimidazole is a therapeutically active method for preparing it

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties